KYMR - CIK 0001815442
Kymera Therapeutics, Inc. trades as KYMR and has a market capitalization of $6.41 B, making it the #1220 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $39.21M, down 16.7% from the prior year and net income of $311.35M. This page tracks Kymera Therapeutics, Inc. through 575 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years Kymera Therapeutics, Inc.'s revenue grew from $2.93M to $39.21M, a compound annual growth rate of 54.0%. Net profit margin expanded from -1405.8% to 794.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-26 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference | Kymera Therapeutics, Inc.
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses | Kymera Therapeutics, Inc.
Kymera Therapeutics to Participate in Upcoming May Investor Conferences | Kymera Therapeutics, Inc.
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week | Kymera Therapeutics, Inc.
The largest companies sharing Kymera Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Kymera Therapeutics, Inc. (KYMR) has a market capitalization of $6.41 B as of 2026-06-10, ranking #1220 among US-listed companies.
Kymera Therapeutics, Inc. reported revenue of $39.21M for fiscal year 2025, a decrease of 16.7% year over year.
Yes. Kymera Therapeutics, Inc. reported net income of $311.35M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update | Kymera Therapeutics, Inc.